這是人胰高血糖素樣肽-1（GLP-1）的合成類似物，并用作GLP-1受體Agonist1。利拉魯肽通過(guò)將精氨酸代替341位的賴氨酸是與天然人類GLP-1同源的97％。通過(guò)將C-16脂肪酸（棕櫚酸）與谷氨酸間隔劑連接在肽前蛋白26的剩余賴氨酸殘基上的C-16脂肪酸（棕櫚酸）來(lái)制造。
It is a synthetic analogue of human glucagon-like peptide-1 (GLP-1) and acts as a GLP-1 receptor Agonist1. Liraglutide is 97% homologous to natural human GLP-1 by substituting arginine for lysine at position 341. It is manufactured by connecting the C-16 fatty acid (palmitic acid) with a glutamate spacer to the C-16 fatty acid (palmitic acid) on the remaining lysine residue of the peptide preprotein 26.
AI產(chǎn)品描述：
2006-2025 上海博華國(guó)際展覽有限公司版權(quán)所有（保留一切權(quán)利）
滬ICP備05034851號(hào)-57
